FDA warns azithromycin "Z-pack" antibiotics could lead to deadly heart rhythms for some Azithromycin, a commonly-prescribed antibiotic, may trigger a potentially deadly irregular heart rhythm for some patients, the Food and Drug Administration (FDA) warned Tuesday. The antibiotic that's sold as Zithromax, Zmax or sometimes referred to as a "Z-Pack" is prescribed to treat bacterial infections such as bronchitis, pneumonia, or ear infections. The FDA is warning the public that the pills can cause abnormal changes in the heart's electrical activity that may lead to a fatal heart rhythm. Not everyone is at risk. Patients with known risk factors such as existing QT interval prolongation, low blood levels of potassium or magnesium, a slower than normal heart rate, or those who use certain drugs to treat abnormal heart rhythms, or arrhythmias face the greatest risk. "Health care professionals should consider the risk of fatal heart rhythms with azithromycin when considering treatment options for patients who are already at risk for cardiovascular events," the FDA said in its March 12th update. The new guidance was prompted by a May 2012 study and another study by the antibiotic's manufacturer, Pfizer, that looked at risks to electrical activity of the heart in azithromycin-takers. Last May, a New England Journal of Medicine study paid for by the National Heart, Lung and Blood Institute found there would be 47 extra heart-related deaths per one million course of treatment with five days of Zithromax, as compared to 10 days of amoxicillin and other antibiotics. The risks of cardiovascular death associated with levofloxacin (Levaquin) treatment were similar to those associated with azithromycin treatment, according to the FDA. "People need to recognize that the overall risk is low," Dr. Harlan Krumholz, a Yale University health outcomes specialist who was not involved in the study, told the Associated Press last May. He added more research was needed but patients with heart disease "should probably be steered away" from Zithromax for now. The FDA also issued a statement last May following the study saying the agency was aware of the findings, and it would review the results and communicate any new information. Sales of Zithromax, one of the U.S.' top-selling antibiotics, totaled $464 million in 2011 according to health care information company IMS Health, the AP reported.